Pembrolizumab plus investigational HPV drugs for throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent.
- Your cancer is oropharyngeal (throat) cancer that is HPV-related (hrHPV positive) and p16-positive, and your tumor PD-L1 score is CPS ≥ 1.
- Your cancer is advanced or recurrent (R/M) and you have not had treatment for the advanced/recurrent disease before; you should be starting pembrolizumab as standard care.
- You must have tumor tissue available (archived or from a new screening biopsy) to confirm HPV and PD-L1 testing; without it, you cannot join.
- Your overall health is good enough: ECOG performance status 0–1 and blood counts/organ function meet required minimums (like neutrophils, platelets, hemoglobin, kidneys, liver).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine made from your own tumor to help your immune system fight head and neck cancer that has returned or spread. It is given alone or with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors or slow progression.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
Hear when a new Metastatic Oropharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.